GET THE APP
Novel Biomarkers Best Journal Articles | Open Access Journals
..

Molecular Biomarkers & Diagnosis

ISSN: 2155-9929

Open Access
Spanish Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil
Submit Manuscript arrow_forward arrow_forward ..

Novel Biomarkers Best Journal Articles

The term biomarker is used to describe a concept familiar to pathologists– a laboratory-measurable analyte which provides information useful in assessing the nature and extent of disease, the response to therapy, or the potential to respond to a proposed therapy.

The various named arthritic pathologies are well-diagnosed by current clinical and laboratory tests, yet there is room for improvement. There are various treatment options, ranging from aspirin to complex biologicals, admixed with treatment to reduce pain. Rheumatologists have established hierarchies of treatment, progressing from simpler to more complex and more expensive treatments depending on response. The aim of novel biomarker studies is to allow identification of the most appropriate treatment at the outset, based on laboratory testing, making the process more effective.

 Due to the target values and convenience of measurement with automated technology within the era, the applications of biomarkers in biomedicine are increasingly broader and vastly important.  Immunohistostaining of molecular markers are widely used for identifying cancer types. FLT3 and nucleophosmin (NPM1) mutations are playing important roles in individualizing treatment decisions on acute chronic myelocytic leukaemia. As an example, Oncotype Dx carcinoma test, a 21-gene panel assay, provides personalized prediction of carcinoma relapse risk and may potentially reduce unnecessary adjuvant chemotherapy. Targeted agents are revolutionizing the cancer therapy.  Trastuzumab, a MoAb blocking Her2/neu, is an indispensible agent for Her2/neu positive carcinoma and metastatic gastric cancer. Bevacizumab, a MoAb binding vascular endothelial protein (VEGF), has been approved for the treatment of a broad spectrum of advanced malignancies like colorectal, brain, kidney and non-small cell lung cancer (NSCLC). Brentuximab vedotin (SGN-35), an immunotoxin conjugate, is now available for CD30 positive anaplastic large cell lymphoma and Hodgkin lymphoma.

 

High Impact List of Articles
Conference Proceedings

Relevant Topics in Genetics & Molecular Biology

Awards & Nominations

50+ Million Readerbase

Journal Highlights

Google Scholar citation report
Citations: 2054

Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report

Citation image
Molecular Biomarkers & Diagnosis peer review process verified at publons
Publon image

Indexed In

Related Links

PMC/PubMed Indexed Articles
Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches

View More »

 

Open Access Journals

arrow_upward arrow_upward